France· FR:69785998
AMIFAMPRIDINE SERB 10 mg, comprimé
A amifampridine product containing phosphate d'amifampridine, registered in France by SERB (BELGIQUE), on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Amifampridine is registered in 16 of 19 countries.
Countries holding a registration under ATC N07XX05 (amifampridine), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Amifampridine · ATC N07XX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amifampridine costs, country by country.
Normalised to the WHO defined daily dose (40 mg), the median price runs from $75.59 in Switzerland to $3657.38 in France — a ×48 gap.
- France: $3657.38 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Amifampridine · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- FR France$3657.38
- CH Switzerland$75.59
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PHOSPHATE D'AMIFAMPRIDINE
- Manufacturer
- SERB (BELGIQUE)
- Country
- France (FR)
- ATC code
- N07XX05
- ATC class
- Amifampridine
- Defined daily dose
- 40 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930252444100 plaquette(s) aluminium PVC-Aluminium PVDC de 1 comprimé (dose unitaire)EUR 803.12
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for amifampridine.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amifampridine · interactions on record
82 records
- 4 severe
- 78 moderate
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- IohexolV08AB02severe
- IopamidolV08AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Amifampridine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAmifampridine Accord 10 mg tablettenAccord Healthcare B.V.
- CzechiaAMIFAMPRIDINE SERBSERB S.A., Brusel
- United Kingdom3,4-Diaminopyridine 10mg tabletsSpecial Order
- PolandAmifampridine Medical ValleyMedical Valley Invest AB
- IcelandAmifampridine SERBSERB S.A.
- NorwayAmifampridine AccordAccord Healthcare B.V.
- CanadaFIRDAPSEKYE PHARMACEUTICALS INC.
- FinlandAmifampridine SERBSERB S.A.
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Germany · Amifampridin Accord, Amifampridin Amarox
- Hungary · Amifampridine Accord
- Iceland · Amifampridine Serb, Firdapse
- Italy · Amifampridina Accord
- Liechtenstein · Amifampridine Serb, Firdapse
- Netherlands · Amifampridine Accord, Amifampridine Amarox
- Norway · Amifampridin Medical Valley, Amifampridine Accord
- Poland · Amifampridine Medical Valley
- Portugal · Amifampridina Accord, Amifampridina Generis
- Slovenia · Amifampridin Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/856db025-c1cb-44f3-bb2c-6be6b003ccc2 GET /v1/drugs/856db025-c1cb-44f3-bb2c-6be6b003ccc2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69785998",
"date_amm": "2022-05-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/22/1646",
"substance": "PHOSPHATE D'AMIFAMPRIDINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about amifampridine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.